Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
Blueprint Medicines Corporation
Modality
Small molecule
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05153408CT.gov (HARMONY) Study of BLU-701 in EGFR-mutant NSCLC | — | Terminated | — | — | — |
NCT04862780CT.gov (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Bronchogenic Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Osimertinib (this asset) | Blueprint Medicines Corporation | P1 | CC · 43 |
| Carboplatin | Nanfang Hospital, Southern Medical University | P3 | BB |
| Cis-Diamminedichloroplatinum Ii | Nanfang Hospital, Southern Medical University | P3 | BB |
| Pralsetinib, Trans- | Hoffmann-La Roche | P3 | BB |
| Vinorelbine Ditartrate | University of Turin, Italy | P3 | B |
| Pembrolizumab | Hoffmann-La Roche | P3 | B |
| Docetaxel | University of Turin, Italy | P3 | B |
| Belagenpumatucel-L (Sk-Lu-1) | NovaRx Corporation | P2 | B |
| Adebrelimab | Nanfang Hospital, Southern Medical University | P2 | CCC |
+9 more in the Bronchogenic Carcinoma cohort
Other indications for Osimertinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Non-Small Cell Lung Carcinoma | — | P4 | BB · 71 |
| Lung Adenocarcinoma | — | P2 | BB · 69 |
| Hepatocellular Carcinoma | — | P3 | BB · 65 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Osimertinib in Bronchogenic Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/osimertinib-bronchogenic-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →